Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 11, 2022
Share
Formosa Laboratories, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 834.94 million compared to TWD 736.28 million a year ago. Net loss was TWD 400.35 million compared to net income of TWD 1,065.81 million a year ago. Basic loss per share from continuing operations was TWD 3.33 compared to basic earnings per share from continuing operations of TWD 9.84 a year ago. Diluted loss per share from continuing operations was TWD 3.33 compared to diluted earnings per share from continuing operations of TWD 8.78 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.